OmniAb (OABI) Research & Development (2022 - 2026)
OmniAb's (OABI) quarterly Research & Development came in at $9.6 million in Q1 2026, down 23.5% year-on-year from $12.6 million in Q1 2025, and down 30.69% on a QoQ basis from $13.9 million in Q4 2025.
OmniAb (OABI) Research & Development (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Research & Development data on file, last reported at $9.6 million in Q1 2026.
- On a quarterly basis, Research & Development fell 23.5% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was $44.8 million, a 15.74% decrease from a year earlier, with the FY2025 full-year figure at $47.8 million, down 13.35% from the prior year.
- Research & Development for Q1 2026 stood at $9.6 million, down from $13.9 million in the prior quarter.
- Over the last five years, Research & Development for OABI reached as high as $14.8 million in Q4 2023 and fell as low as $9.6 million in Q1 2026.
- Historically, Research & Development has averaged $12.8 million across 5 years, with a median of $13.3 million in 2024.
- Across the five-year window, Research & Development rose 27.73% in 2023 and slipped 23.5% in 2026, its largest moves.
- Year by year, Research & Development stood at $12.9 million in 2022, then rose by 14.3% to $14.8 million in 2023, then decreased by 9.89% to $13.3 million in 2024, then increased by 4.53% to $13.9 million in 2025, then sank by 30.69% to $9.6 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $9.6 million in Q1 2026, $13.9 million in Q4 2025, and $10.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | OmniAb | 263.54 Mn | 214.47 Mn | 14.41 Mn | 9.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.64 Mn |
| Dec 31, 2025 | 13.91 Mn |
| Sep 30, 2025 | 10.38 Mn |
| Jun 30, 2025 | 10.86 Mn |
| Mar 31, 2025 | 12.60 Mn |
| Dec 31, 2024 | 13.31 Mn |
| Sep 30, 2024 | 13.32 Mn |
| Jun 30, 2024 | 13.94 Mn |
| Mar 31, 2024 | 14.55 Mn |
| Dec 31, 2023 | 14.77 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 14.13 Mn |
| Mar 31, 2023 | 13.76 Mn |
| Dec 31, 2022 | 12.92 Mn |
| Sep 30, 2022 | 13.19 Mn |
| Jun 30, 2022 | 11.48 Mn |
| Mar 31, 2022 | 10.77 Mn |